The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Hot spots in dynamic18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas
Open accessAbstract
Molecular imaging studies have recently found inter- and intratumoral heterogeneity in World Health Organization (WHO) grade II gliomas. A correlative analysis with tumor histology, however, is still lacking. For elucidation we conducted the current prospective study. Fifty-five adult patients with an MRI-based suspicion of a WHO grade II glioma were included. [F-18]Fluoroethyltyrosine ((18)FET) uptake kinetic studies were combined with frame-based stereotactic localization techniques and used as a guide for stepwise (1-mm steps) histopathological evaluation throughout the tumor space. In tumors with heterogeneous PET findings, the O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and expression of mutated protein isocitrate dehydrogenase variant R132H (IDH1) were determined inside and outside of hot spot volumes. Metabolic imaging revealed 3 subgroups: the homogeneous WHO grade II glioma group (30 patients), the homogeneous malignant glioma group (10 patients), and the heterogeneous group exhibiting both low- and high-grade characteristics at different sites (15 patients). Stepwise evaluation of 373 biopsy samples indicated a strong correlation with analyses of uptake kinetics (p < 0.0001). A homogeneous pattern of uptake kinetics was linked to homogeneous histopathological findings, whereas a heterogeneous pattern was associated with histopathological heterogeneity; hot spots exhibiting malignant glioma characteristics covered 4-44% of the entire tumor volumes. Both MGMT and IDH1 status were identical at different tumor sites and not influenced by heterogeneity. Maps of (18)FET uptake kinetics strongly correlated with histopathology in suspected grade II gliomas. Anaplastic foci can be accurately identified, and this finding has implications for prognostic evaluation and treatment planning.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
Self-citation
Cited by
Albert, N. L., Weller, M., Suchorska, B., Galldiks, N., Soffietti, R., Kim, M. M., la Fougère, C., Pope, W., Law, I., Arbizu, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now058 · Cited by 744
Self-citationAndronesi, O. C., Kim, G. S., Gerstner, E., Batchelor, T., Tzika, A. A., Fantin, V. R., Vander Heiden, M. G., & Sorensen, A. G. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002693 · Cited by 438
“Moreover, MRS methods could map 2HG distribution and identify 2HG hot spots, guiding biopsy procedures to increase the chances for correct typing of the tumor, because it is known that biopsy based on conventional computed tomography (CT) or magnetic resonance imaging (MRI) is suboptimal and subject to undergrading (2…”
BackgroundMethodHadjipanayis, C. G., Widhalm, G., & Stummer, W. (2015) · Neurosurgery · doi:10.1227/neu.0000000000000929 · Cited by 369
Advances in neuro-oncology imaging
Langen, K.-J., Galldiks, N., Hattingen, E., & Shah, N. J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.44 · Cited by 339
Molecular imaging of gliomas with PET: Opportunities and limitations
la Fougere, C., Suchorska, B., Bartenstein, P., Kreth, F.-W., & Tonn, J.-C. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor054 · Cited by 274
Self-citation
Metadata
- Authors
- Kunz, M., Thon, N., Eigenbrod, S., Hartmann, C., Egensperger, R., Herms, J., Geisler, J., la Fougere, C., Lutz, J., Linn, J., Kreth, S., von Deimling, A., Tonn, J. C., Kretzschmar, H. A., Popperl, G., & Kreth, F. W.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-02-03
- Volume
- 13
- Issue
- 3
- Pages
- 307-316
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2103674995
- Cited by
- 246
- References
- 3
- FWCI
- 8.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hot spots in dynamic18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. https://app.cochat.ai/papers/10.1093/neuonc/noq196
- The paper
- Kunz, M., Thon, N., Eigenbrod, S., Hartmann, C., Egensperger, R., Herms, J., Geisler, J., la Fougere, C., Lutz, J., Linn, J., Kreth, S., von Deimling, A., Tonn, J. C., Kretzschmar, H. A., Popperl, G., & Kreth, F. W. (2011). Hot spots in dynamic18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/noq196
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.